Overview

Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors

Status:
Terminated

Trial end date:
2016-08-01

Target enrollment:

Participant gender:

Summary

The investigators hypothesize that the new imaging method Gallium-68-DOTATATE has a higher diagnostic value in the detection of neuroendocrine tumors than the established imaging method Indium-111-Octreoscan. Therefore, the investigators will perform both imaging procedures in patients with suspected or confirmed neuroendocrine tumors. Subsequently, the investigators will compare the diagnostic performance of both methods.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

University Hospital Inselspital, Berne

Collaborators:

SWAN Isotopen AG, Bern
University Hospital, Basel, Switzerland
University of Bern
University of Lausanne Hospitals

Treatments:

Somatostatin